TEVA — Teva Pharmaceutical Industries Income Statement
0.000.00%
Last trade - 00:00HealthcareBalancedMicro Cap
Annual income statement for Teva Pharmaceutical Industries, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 16,887 | 16,659 | 15,878 | 14,925 | 15,846 |
| Cost of Revenue | |||||
| Gross Profit | 7,536 | 7,789 | 7,864 | 7,438 | 7,976 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 17,330 | 20,231 | 14,162 | 17,122 | 15,413 |
| Operating Profit | -443 | -3,572 | 1,716 | -2,197 | 433 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,265 | -4,406 | 658 | -3,163 | -624 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -987 | -4,238 | 447 | -2,520 | -617 |
| Minority Interest | |||||
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -998 | -3,991 | 417 | -2,446 | -559 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -999 | -3,990 | 417 | -2,446 | -559 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.985 | 0.356 | 1.42 | 1.02 | 1.35 |
| Dividends per Share |